NO951147L - Substituted heterocyclic carboxylic acid esters, their preparation and their use as a drug - Google Patents

Substituted heterocyclic carboxylic acid esters, their preparation and their use as a drug

Info

Publication number
NO951147L
NO951147L NO951147A NO951147A NO951147L NO 951147 L NO951147 L NO 951147L NO 951147 A NO951147 A NO 951147A NO 951147 A NO951147 A NO 951147A NO 951147 L NO951147 L NO 951147L
Authority
NO
Norway
Prior art keywords
stands
carboxylic acid
residue
drug
preparation
Prior art date
Application number
NO951147A
Other languages
Norwegian (no)
Other versions
NO951147D0 (en
Inventor
Klaus Weidmann
Karl-Heinz Baringhaus
Georg Tschank
Martin Bickel
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO951147D0 publication Critical patent/NO951147D0/en
Publication of NO951147L publication Critical patent/NO951147L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det blir beskrevet substituerte heterocykliske karboksylsyreamidestere med den generelle formel l (D hvor O står for O, S eller NRT, X står for O eller S, Y står for CR3 eller N, m står for O og l , A står for eventuelt substituert (C^-C^ )-alkylen, B står for -C02V, R1 og R3 er Ilke eller forskjellige og står for hydrogen, (Cj-Cgi-alkyl , (Cj-CgJ-alkoksy , halogen, hydroksy, eventuelt substituert amlno, alkylkarbonyloksy , R2 står for en karboksylsyrelsostergruppe, R* står for en forgrenet eller uforgrenet alkylrest, en (C^-CKj-arylrest , en (C- alkylrest, en heteroarylrest eller en heteroaralkyl- rest, eller R1 og R4 kan danne en kjede [CH2]0, en eller to grupper kan være erstattet av et heteroatom. Det er også beskrevet en fremgangsmåte for fremstilling av disse forbindelsene. De nevnte forbindelsene finner deres anvendelse som legemiddel mot flbrotlske sykdommer og som hemmere av prolylhydroksylasen og kollagenblosyntesen.Substituted heterocyclic carboxylic acid esters of general formula I are described (D where O stands for O, S or NRT, X stands for O or S, Y stands for CR 3 or N, m stands for O and 1, A stands for optionally substituted ( The C 1 -C 4 alkylene, B stands for -CO 2 V, R 1 and R 3 are the same or different and represent hydrogen, (C 1 -C 8 alkyl, (C 1 -C 8 alkoxy, halogen, hydroxy, optionally substituted amino, alkylcarbonyloxy) , R 2 represents a carboxylic acid ester group, R * represents a branched or unbranched alkyl residue, a (C 1 -C 8 aryl residue, a (C 1-6 alkyl residue, a heteroaryl residue or a heteroaralkyl residue), or R 1 and R 4 may form a chain [CH 2 ] 0, one or two groups may be replaced by a heteroatom A process for the preparation of these compounds is also disclosed, said compounds finding their use as a drug for multicellular diseases and as inhibitors of the prolyl hydroxylase and collagen bloc synthesis.

NO951147A 1994-03-25 1995-03-24 Substituted heterocyclic carboxylic acid esters, their preparation and their use as a drug NO951147L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4410453A DE4410453A1 (en) 1994-03-25 1994-03-25 Substituted heterocyclic carboxylic acid amide esters, their preparation and their use as medicaments

Publications (2)

Publication Number Publication Date
NO951147D0 NO951147D0 (en) 1995-03-24
NO951147L true NO951147L (en) 1995-09-26

Family

ID=6513880

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951147A NO951147L (en) 1994-03-25 1995-03-24 Substituted heterocyclic carboxylic acid esters, their preparation and their use as a drug

Country Status (12)

Country Link
EP (1) EP0673930A1 (en)
JP (1) JPH07278111A (en)
KR (1) KR950032127A (en)
AU (1) AU1504495A (en)
CA (1) CA2145473A1 (en)
CZ (1) CZ73595A3 (en)
DE (1) DE4410453A1 (en)
FI (1) FI951388A (en)
HU (1) HUT72596A (en)
NO (1) NO951147L (en)
PL (1) PL307846A1 (en)
ZA (1) ZA952410B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206711D0 (en) 2002-03-21 2002-05-01 Isis Innovation HIF Inhibitor
US8558002B2 (en) 2006-11-16 2013-10-15 Allergan, Inc. Sulfoximines as kinase inhibitors
JP2010510242A (en) * 2006-11-16 2010-04-02 アラーガン、インコーポレイテッド Sulfoximine as a kinase inhibitor
RS60906B1 (en) 2014-10-06 2020-11-30 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
EP3436446B1 (en) 2016-03-31 2023-06-07 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
SG10201913595YA (en) 2016-09-30 2020-02-27 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
IL294237A (en) 2016-12-09 2022-08-01 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
NZ760052A (en) 2017-06-08 2024-07-05 Vertex Pharma Methods of treatment for cystic fibrosis
US11517564B2 (en) 2017-07-17 2022-12-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
MA49752A (en) 2017-08-02 2021-04-21 Vertex Pharma PROCESSES FOR THE PREPARATION OF PYRROLIDINE COMPOUNDS
AU2018351533B2 (en) 2017-10-19 2023-02-02 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
EP3720849A2 (en) 2017-12-08 2020-10-14 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (en) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 Pharmaceutical compositions for treating cystic fibrosis
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
CZ73595A3 (en) 1995-11-15
KR950032127A (en) 1995-12-20
FI951388A0 (en) 1995-03-23
CA2145473A1 (en) 1995-09-26
NO951147D0 (en) 1995-03-24
PL307846A1 (en) 1995-10-02
JPH07278111A (en) 1995-10-24
FI951388A (en) 1995-09-26
AU1504495A (en) 1995-10-05
DE4410453A1 (en) 1995-09-28
EP0673930A1 (en) 1995-09-27
HUT72596A (en) 1996-05-28
ZA952410B (en) 1995-12-01

Similar Documents

Publication Publication Date Title
NO951147L (en) Substituted heterocyclic carboxylic acid esters, their preparation and their use as a drug
DE59401923D1 (en) Substituted heterocyclic carboxylic acid amide esters, their preparation and their use as medicaments
PT76316A (en) Process for the preparation of esters of substituted pyridino- 3,5-dicarboxylic and/or of pyrano-3,5-dicarboxylic acids having an hypotensive effect and application thereof for the preparation of pharmaceutical compositions having an hypotensive effect
ATE149486T1 (en) SUBSTITUTED HETEROCYCLIC CARBOXYLIC AMIDES, THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS
DK446279A (en) PROCEDURE FOR PREPARING SUBSTITUTED 1-CARBA-2-PENEM-3-CARBOXYL ACIDS
SE8303208L (en) Heterocyclic Associations
WO2000046198A8 (en) Anti-inflammatory indole derivatives
PT83310A (en) HETEROCYCLIC SUBSTITUTED INDOLE INTERMEDIATE PRODUCTS PROCESS FOR THEIR MANUFACTURE AND MEDICAMENTS
DE3167757D1 (en) Dibenz(b,f)(1,4)oxazepine derivatives, process for preparing the same, and pharmaceutical compositions comprising the same
NO302470B1 (en) Substituted heterocyclic carboxylic acid amides, and their use in the manufacture of drug
SE423812B (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE DERIVATIVES OF AZETIDINE-2-CARBOXYLIC ACID, PROLINE AND PIPECOLIC ACID
ATE302778T1 (en) N-SUBSTITUTED 4-AMINOPTERIDINES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS
ES2123652T3 (en) 7- (2-AMINOETIL) -BENZOTIAZOLONAS.
AU633408B2 (en) New imidazo (1,2-c) derivatives, process for the preparation thereof and pharmaceutical compositions containing them
DE69624582D1 (en) ESTER AND AMIDE AS PLA2 INHIBITORS
ZA815043B (en) Diazepine derivatives,process for their preparation,and pharmaceutical compositions thereof
US4483861A (en) Antihypertensive sulfur-containing compounds
PT76328B (en) Process for the preparation of pyridinocarboxylic acids esters having an anti-ischemic and anti-hypoxygenic effect and application thereof for the preparation of pharmaceutical compositions having an anti-ischemic and anti-hypoxygenic effect
ES2016017A6 (en) 1,1-dioxo-cephem-4-carbothiolic acid derivatives.
EP0802179A4 (en) Substituted amidinonaphthyl ester derivatives
ATE56437T1 (en) PROCESS FOR THE PREPARATION OF 1,4DIHYDROPYRIDE DERIVATIVES VIA NOVEL INTERMEDIATE PRODUCTS.
NO20020561L (en) Process for the preparation of acids via alpha-chloro-epoxy esters